Gastrointestinal Cancer | Specialty

Dr. Zafar on Low BMI Impact on Colorectal Cancer Survival

July 1st 2015

S. Yousuf Zafar, MD, Associate Professor of Medicine at Duke Cancer Institute, discusses the potential link between low body mass index (BMI) and survival outcomes in metastatic colorectal cancer.

Panitumumab in CRC, Ramucirumab in HCC, 13th ICML, and More

June 26th 2015

Dr. James Lee on Overcoming Mismatched Repair in Colorectal Cancer

June 25th 2015

James J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer.

Case Study: 33-Year-Old With Liver-Metastatic Colorectal Cancer

June 25th 2015

Radiofrequency Ablation in Colorectal Cancer Liver Metastases

June 25th 2015

SIRFLOX Study in Liver-Metastatic Colorectal Cancer

June 25th 2015

Radioembolization for CRC Liver Metastases

June 25th 2015

RAS Mutation Status in Colorectal Cancer

June 25th 2015

Liver Resectability in Metastatic Colorectal Cancer

June 25th 2015

Treating Liver Metastases in Colorectal Cancer

June 25th 2015

Controlling Liver Metastases in Colorectal Cancer

June 25th 2015

MM-398 Receives Priority Review for Advanced Pancreatic Cancer

June 25th 2015

The FDA has assigned a priority review designation to MM-398 in combination with 5-fluorouracil and leucovorin for patients with metastatic pancreatic cancer following treatment with a gemcitabine-based therapy.

Ramucirumab HCC Data Published Amid Launch of Second Phase III Trial

June 19th 2015

Second-line treatment with ramucirumab did not improve overall survival compared with placebo in the full population of patients with advanced hepatocellular carcinoma examined in the phase III REACH study.

Panitumumab Improves OS Versus Supportive Care in Phase III mCRC Trial

June 19th 2015

Patients with chemorefractory KRAS wild-type metastatic colorectal cancer had a statistically significant improvement in overall survival when treated with panitumumab (Vectibix) versus best supportive care, according to data released from a phase IlI study.

PEGPH20 Combination Doubles PFS in HA-High Pancreatic Cancer

June 16th 2015

The addition of PEGPH20 to standard nab-paclitaxel and gemcitabine improved progression-free survival by 4.9 months compared with the two agents alone in untreated patients with advanced pancreatic cancer who expressed high-levels of hyaluronan.

Preventing and Managing Regorafenib-Related Hand-Foot Skin Reaction

June 14th 2015

Many oncology professionals who treat patients on regorafenib are unfamiliar with how to manage and prevent hand-foot skin reaction.

Selective Internal Radiation Therapy Effective in Some Patients With mCRC

June 12th 2015

Adding liver-direceted Yttrium-90 resin microspheres to frontline FOLFOX-based chemotherapy improved liver-specific progression-free survival by 7.9 months for patients with colorectal cancer with liver-dominant metastases.

Dr. Goldberg on PD-1 Blockade in Tumors with Mismatch Repair Deficiency

June 12th 2015

Richard Goldberg, MD, Ohio State University Comprehensive Cancer Center-James Cancer Hospital, discusses PD-1 blockade in tumors with mismatch repair deficiency.

Dr. Dalgleish on IMM-101 With Gemcitabine for Pancreatic Cancer

June 10th 2015

Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMedSci, professor, Department of Oncology, St. George's, University of London, discusses a study that examined the combination of an immunomodulator with gemcitabine in patients with pancreatic cancer.

Triplet Therapy Effective in BRAF-mutant mCRC

June 8th 2015

The combination of dabrafenib, trametinib, and panitumumab showed promising clinical activity in BRAFV600E-mutated metastatic colorectal cancer.